Free Trial
NASDAQ:AIFF

Firefly Neuroscience Q2 2025 Earnings Results & Report

Firefly Neuroscience logo
$0.98 +0.00 (+0.06%)
As of 09:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Firefly Neuroscience reported Q2 2025 earnings on August 13, 2025. The company reported EPS of -$0.14.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Firefly Neuroscience EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Firefly Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Firefly Neuroscience Q2 2025 Earnings FAQ

Firefly Neuroscience (NASDAQ:AIFF) reported earnings of -$0.14 per share for Q2 2025. The report was announced on Wednesday, August 13, 2025.

Firefly Neuroscience Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Firefly Hikes on Partnering with NeuroSigma
See More Firefly Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Firefly Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Firefly Neuroscience and other key companies, straight to your email.

About Firefly Neuroscience

Firefly Neuroscience (NASDAQ:AIFF) is a digital health and neuroscience company focused on using artificial intelligence to support the assessment and treatment of brain disorders. The company develops technology designed to analyze electroencephalography (EEG) data and identify patterns associated with cognitive and psychiatric conditions.

Its principal platform, Brain Network Analytics (BNA), is intended to convert EEG recordings into clinically relevant measures of brain function. Firefly’s technology is designed to help healthcare professionals evaluate conditions such as Alzheimer’s disease and major depressive disorder, monitor changes in patients’ brain activity, and support more personalized treatment decisions.

Firefly Neuroscience became a publicly traded company on Nasdaq under the symbol AIFF following a business combination with WaveDancer, Inc. in 2024. The company serves the healthcare and life sciences markets, although publicly available information provides limited detail about its geographic operations and commercial reach.

View Firefly Neuroscience Profile